- Home
- ARVN vs TTGT Comparison
ARVN vs TTGT Comparison
Compare ARVN & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- TTGT
- Stock Information
- Founded
- ARVN 2015
- TTGT 1999
- Country
- ARVN United States
- TTGT United States
- Employees
- ARVN N/A
- TTGT N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- TTGT Telecommunications Equipment
- Sector
- ARVN Health Care
- TTGT Telecommunications
- Exchange
- ARVN Nasdaq
- TTGT Nasdaq
- Market Cap
- ARVN 456.2M
- TTGT 468.3M
- IPO Year
- ARVN 2018
- TTGT 2007
- Fundamental
- Price
- ARVN $7.90
- TTGT $5.53
- Analyst Decision
- ARVN Buy
- TTGT Strong Buy
- Analyst Count
- ARVN 22
- TTGT 5
- Target Price
- ARVN $20.21
- TTGT $16.40
- AVG Volume (30 Days)
- ARVN 1.8M
- TTGT 630.9K
- Earning Date
- ARVN 10-29-2025
- TTGT 08-12-2025
- Dividend Yield
- ARVN N/A
- TTGT N/A
- EPS Growth
- ARVN N/A
- TTGT N/A
- EPS
- ARVN N/A
- TTGT N/A
- Revenue
- ARVN $372,800,000.00
- TTGT $387,100,000.00
- Revenue This Year
- ARVN $4.87
- TTGT N/A
- Revenue Next Year
- ARVN N/A
- TTGT $99.41
- P/E Ratio
- ARVN N/A
- TTGT N/A
- Revenue Growth
- ARVN 299.57
- TTGT 50.73
- 52 Week Low
- ARVN $5.90
- TTGT $5.39
- 52 Week High
- ARVN $29.61
- TTGT $33.08
- Technical
- Relative Strength Index (RSI)
- ARVN 60.55
- TTGT 33.12
- Support Level
- ARVN $7.62
- TTGT $5.81
- Resistance Level
- ARVN $8.22
- TTGT $6.23
- Average True Range (ATR)
- ARVN 0.31
- TTGT 0.31
- MACD
- ARVN 0.10
- TTGT -0.02
- Stochastic Oscillator
- ARVN 76.98
- TTGT 13.46
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.